<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2023</year>
    <pub-dates>
     <date>2023-01-25</date>
    </pub-dates>
   </dates>
   <doi>10.1016/j.bmcl.2022.129097</doi>
   <abstract>Acute lung injury (ALI) is a devastating disease with a high mortality rate of 30%–40%. There is an unmet&#13;
clinical need owing to limited treatment strategies and little clinical benefit. The pathology of ALI indicates that&#13;
reducing the inflammatory response could be a highly desirable strategy to treat ALI. In this study, we designed&#13;
and synthesized 36 novel 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives and evaluated their anti-inflammatory&#13;
activities by measuring the release of cytokines in lipopolysaccharide (LPS)-challenged J774A.1 cells. Compounds 19, 20, and 39 potently reduced the release of IL-6 and TNF-α in J774A.1 cells. Additionally, 39&#13;
improved LPS-induced ALI in vivo and inhibited cytokine production in lung tissues. Furthermore, 39 reduced&#13;
inflammatory infiltration and downregulated p-p65 levels in lung tissues. Thus, compound 39 could serve as a&#13;
new lead structure for the development of anti-inflammatory drugs to treat ALI.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/3938</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/4114</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
